Generalized myasthenia gravis (gMG) affects most patients through a handful of well-characterized neuromuscular junction ...

As we observe Rare Disease Day today, let us take a look at seven drugs poised to be approved to address rare diseases in ...

Argenx had cash, cash equivalents, and other short-term investments totaling $3.4 billion as of the end of 2024, making it well-positioned to continue funding its pipeline and commercialization ...

In the generalized myasthenia gravis (gMG) market, where JNJ plans to launch Nipocalimab in late 2025, the company will face competition from established players. However, analysts believe there is ...

Nipocalimab binds FcRn with high specificity, reducing IgG levels while sparing innate and adaptive immune functions. Nipocalimab effectively reduced maternal alloantibodies implicated in fetal and ...

that are integral to the pathogenesis of generalized myasthenia gravis," noted Richard Nowak, MD, MS, of Yale University in New Haven, Connecticut. In the Vivacity-MG3 trial, nipocalimab lessened ...

In part 4 of our interview, we learn more about nipocalimab’s safety profile and how this investigative agent might address unmet needs for patients with generalized myasthenia gravis.

Myasthenia gravis (MG) should be classified according to antibody status (acetylcholine, MuSK, LRP4, titin), thymus (hyperplasia, neoplasia, atrophy), age at debut (< or >50 years), symptom ...

diabetes and myasthenia gravis. COUR will be facing some major Big Pharma peers in myasthenia; Argenx’s Vyvgart was approved for the disease in 2021 while Johnson & Johnson has filed for approval of ...

Biopharma doubles down on immunology and inflammation as companies target new pathways and seek to improve on current options in inflammatory bowel disease, atopic dermatitis, myasthenia gravis and ...